Product development at SYBD is taking place on several innovative technological platforms:

Fluorovent, a proprietary oxygen-carrying fluorocarbon, is a highly effective medium for gas exchange. It is effective in increasing pulmonary function and the diffusion of oxygen and carbon dioxide in cases of respiratory distress.

Oxycyte is an oxygen-carrying intravenous emulsion that can carry five times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carbon dioxide to the lungs for disposal. New applications of oxygen therapeutic agents include stroke, myocardial infarction, and certain malignant diseases.

The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. The most accurate glucose monitor available, SYBD’s implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.

Based on studies to date, all SYBD products offer significant competitive advantages:

Fluorovent:

• longer pulmonary retention, reducing need for replacing exhaled fluid
• potentially less costly, less labor intensive
• environmentally safe - no bromine or chlorine
• does not cause hyperinflated, non-collapsible lung syndrome

Oxycyte:

• slower exhalation rate results in longer effective blood circulation half-life
• environmentally safe - no bromine or chlorine
• no potential for hyperinflated, non-collapsible lung condition

Implanted Glucose Biosensor:

• significantly more accurate in glucose range of 30-500 mg/dl
• accurate to an oxygen saturation as low as 2%
• extended implant life with stable, linear response
• fully implanted; completely non-invasive after implant
• eliminates patient compliance factor in achieving tight glucose control